Related Experiment Video
Updated: May 30, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
[Tocilizumab in rheumatoid arthritis]
Javier Rueda Gotor1, Ricardo Blanco Alonso
1Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, Santander, España. ruedagotor@gmail.com
Reumatologia Clinica
|July 29, 2011
Summary
Tocilizumab (TCZ) effectively treats rheumatoid arthritis (RA) across various patient groups, including those unresponsive to other therapies. This interleukin-6 receptor inhibitor demonstrates consistent efficacy, safety, and prevents structural damage, making it a valuable RA treatment option.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Tocilizumab (TCZ) is a monoclonal antibody targeting the interleukin-6 (IL-6) receptor.
- It is approved for rheumatoid arthritis (RA) treatment in major global markets.
Purpose of the Study:
- To review the efficacy and safety of TCZ in diverse RA patient populations.
- To evaluate TCZ's role in managing RA, including its impact on laboratory markers and structural damage.
Main Methods:
- Review of clinical trial data (AMBITION, SATORI, OPTION, LITHE, TOWARD, ROSE, RADIATE, GROWTH95, GROWTH96).
- Analysis of TCZ's efficacy in various RA treatment scenarios, including monotherapy and combination therapy.
- Assessment of TCZ's effects on inflammatory markers and joint structural damage.
Main Results:
- TCZ demonstrates consistent efficacy in RA patients, regardless of prior treatment history or biologic use.
- Early and sustained improvement in disease activity and laboratory markers, including anemia of inflammation.
- Effective in preventing structural joint damage and well-tolerated, comparable to other biologic therapies.
Conclusions:
- Tocilizumab is a safe and effective therapeutic option for rheumatoid arthritis across multiple clinical scenarios.
- Its consistent efficacy, safety profile, and disease-modifying properties support its consideration in RA management.
- TCZ offers a valuable treatment alternative for patients with RA, including those refractory to other therapies.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...